- Home
- AMPX vs AARD Comparison
AMPX vs AARD Comparison
Compare AMPX & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMPX
- AARD
- Stock Information
- Founded
- AMPX 2008
- AARD 2017
- Country
- AMPX United States
- AARD United States
- Employees
- AMPX N/A
- AARD N/A
- Industry
- AMPX Industrial Machinery/Components
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- AMPX Miscellaneous
- AARD Health Care
- Exchange
- AMPX Nasdaq
- AARD Nasdaq
- Market Cap
- AMPX 331.4M
- AARD 216.6M
- IPO Year
- AMPX N/A
- AARD 2025
- Fundamental
- Price
- AMPX $2.69
- AARD $7.42
- Analyst Decision
- AMPX Strong Buy
- AARD Strong Buy
- Analyst Count
- AMPX 8
- AARD 4
- Target Price
- AMPX $8.75
- AARD $31.50
- AVG Volume (30 Days)
- AMPX 4.2M
- AARD 122.4K
- Earning Date
- AMPX 03-20-2025
- AARD 01-01-0001
- Dividend Yield
- AMPX N/A
- AARD N/A
- EPS Growth
- AMPX N/A
- AARD N/A
- EPS
- AMPX N/A
- AARD N/A
- Revenue
- AMPX $24,167,000.00
- AARD N/A
- Revenue This Year
- AMPX $165.15
- AARD N/A
- Revenue Next Year
- AMPX $227.50
- AARD N/A
- P/E Ratio
- AMPX N/A
- AARD N/A
- Revenue Growth
- AMPX 166.95
- AARD N/A
- 52 Week Low
- AMPX $0.61
- AARD $6.79
- 52 Week High
- AMPX $4.21
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- AMPX 50.70
- AARD N/A
- Support Level
- AMPX $2.07
- AARD N/A
- Resistance Level
- AMPX $3.37
- AARD N/A
- Average True Range (ATR)
- AMPX 0.30
- AARD 0.00
- MACD
- AMPX 0.09
- AARD 0.00
- Stochastic Oscillator
- AMPX 50.53
- AARD 0.00
About AMPX Amprius Technologies Inc.
Amprius Technologies Inc is engaged in the production of silicon anodes for high-energy-density lithium-ion batteries. The company develops, manufactures and markets lithium-ion batteries for mobility applications, including the aviation, electric vehicle (EV) and light electric vehicle (LEV) industries. The company's batteries are used for existing and emerging aviation applications, including unmanned aerial systems, such as drones and high-altitude pseudo satellites.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.